GlassScriptPhysician profile
Paul Robert Brezina
NPI 1710186473
$1,937.78
in general payments reported to CMS, 2019-2025
13 companies · $247 in 2025
The $247 reported for 2025 was more than what a typical Reproductive Endocrinology provider received nationally (typical 2025 total: $140).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $749 · 2020: $16.19 · 2021: $61.77 · 2022: $432 · 2023: $111 · 2024: $322 · 2025: $247.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $660 · Consulting Fee: $18.79.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $660.23 |
| Consulting Fee | $18.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acessa Health INC. | $676.60 | 2019 | |
| Coopersurgical, INC. | $302.52 | 2022-2025 | Stripper, Origio Sequential Fert |
| Vitrolife INC. | $282.50 | 2022-2025 | Follicle Aspiration Set Single Lumen |
| Emd Serono, INC. | $154.78 | 2019-2025 | |
| Abbvie INC. | $129.95 | 2019-2023 | Orilissa |
| Astellas Pharma US INC | $121.26 | 2024 | |
| Ferring Pharmaceuticals INC. | $114.87 | 2019-2025 | Menopur |
| Organon LLC | $44.64 | 2023-2024 | |
| Merck Sharp & Dohme LLC | $33.68 | 2019-2020 | |
| Hologic Sales and Service, LLC | $32.36 | 2024 | Myosure Tissue Removal Device |
| Boston Scientific Corporation | $19.47 | 2023 | Artisan |
| Medtronic, INC. | $14.20 | 2023 | Truclear |
| Meditrina | $10.95 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Brezina listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.